CD40L Antagonism in Rheumatoid Arthritis (RA)
| 대상 질환 | Rheumatoid Arthritis |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | National Institute of Allergy and Infectious Diseases (NIAID) |
| 상태 | 조기 종료 |
| 참여자 수 | 2 명 |
| 중재(약물) | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi |
| 시작일 | 2023년 7월 25일 |
| 완료일 | 2025년 7월 28일 |
| 결과 공개일 | 2026년 7월 20일 |
요약
The primary objective is to determine if the addition of a 12-week course of treatment with VIB4920 to TNFi treatment will result in improved clinical disease control in patients with RA who have had an inadequate response to a TNFi.
Proportion of Participants Achieving Low Disease Activity by Simplified Disease Activity Index (SDAI)
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.